{"id":"W2313872863","doi":"10.1158/0008-5472.sabcs11-p1-17-01","title":"P1-17-01: Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial.","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Exemestane; Medicine; Clinical endpoint; Internal medicine; Interim analysis; Breast cancer; Oncology; Metastatic breast cancer; Randomized controlled trial; Clinical trial; Cancer; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001112193,0.0008243,0.002629142,0.0005286896,0.0006287951,0.00006499673,0.0008681673,0.0002811385,0.004550249],"category_scores_gemma":[0.0003009292,0.0006638293,0.0002640783,0.001373875,0.001546404,0.0006437512,0.0004725359,0.0006621126,0.00004770493],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004329725,"about_ca_system_score_gemma":0.003126705,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01395193,"about_ca_topic_score_gemma":0.0008550723,"domain_scores_codex":[0.993668,0.0005348014,0.001256468,0.001373763,0.001592716,0.001574252],"domain_scores_gemma":[0.9947658,0.0008570849,0.0005686298,0.001373862,0.001599918,0.0008347007],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8254986,0.006599291,0.000003120186,0.0001062437,0.001589119,0.0002679716,0.002726606,0.00002222583,0.02423861,0.0002432365,0.001574627,0.1371303],"study_design_scores_gemma":[0.89646,0.05017814,0.00003328648,0.0007528122,0.0005796412,0.0001074166,0.0006550519,0.0000618339,0.03188022,0.0003070683,0.01836895,0.000615602],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9114631,0.04158066,0.0001461515,0.004360404,0.001344433,0.02048221,0.01552974,0.0002267276,0.004866546],"genre_scores_gemma":[0.8965335,0.06375357,0.002999619,0.0003251966,0.001457571,0.02079451,0.002423303,0.0004153291,0.01129744],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1365147,"threshold_uncertainty_score":0.9995813,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1443047070812785,"score_gpt":0.4505939564901019,"score_spread":0.3062892494088234,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}